Interchangeability is a regulatory designation that allows a biosimilar medication to be substituted for its brand-name counterpart at the pharmacy without the prescribing doctor’s approval. It works much like how pharmacists routinely swap brand-name drugs for generics. But because biologic medications are complex, made from living cells rather than simple chemical formulas, earning that interchangeable label requires a higher bar of evidence than a standard biosimilar approval.
How Interchangeability Differs From Biosimilarity
All interchangeable products are biosimilars, but not all biosimilars are interchangeable. A biosimilar is a biologic medication that is highly similar to an already-approved reference product with no clinically meaningful differences in safety or effectiveness. To earn the interchangeability designation, a manufacturer must meet additional requirements showing that patients can safely switch back and forth between the biosimilar and the original without losing effectiveness or facing new safety risks.
The practical distinction matters at the pharmacy counter. A standard biosimilar typically requires the prescriber to specifically write it on the prescription or authorize the switch. An interchangeable biosimilar can be dispensed in place of the reference product automatically, depending on state law, just as a pharmacist might hand you generic ibuprofen when your doctor wrote a prescription for the brand name.
What Manufacturers Must Prove
The FDA has historically expected manufacturers seeking interchangeability to conduct switching studies. In these studies, one group of patients alternates between the reference product and the proposed interchangeable biosimilar (at least three switches, ending on the biosimilar), while a control group stays on the reference product alone. Researchers then compare the two groups, looking for any decrease in effectiveness, increase in side effects, or differences in how the immune system responds to the medication.
However, the FDA’s stance on switching studies has shifted significantly. Of the 13 biosimilars approved as interchangeable through mid-2024, nine were approved without additional switching study data. In June 2024, the FDA issued draft guidance proposing that switching studies will generally no longer be needed. The reasoning: real-world experience with biosimilar products approved so far has shown that the risk of safety problems or reduced effectiveness after switching is insignificant. A systematic review and meta-analysis conducted by FDA researchers found no differences in death rates, serious adverse events, or treatment discontinuations between patients who switched and those who didn’t. Immune-related reactions like anaphylaxis, hypersensitivity, and injection site reactions were also similar in both groups.
The FDA also noted that today’s analytical tools can evaluate the structure and biological effects of these products with more precision and sensitivity than switching studies provide. This shift could lower the cost and time needed to bring interchangeable biosimilars to market, since comparative clinical studies typically take one to three years and cost an average of $24 million.
How Pharmacy Substitution Works in Practice
When a biosimilar earns interchangeability status, the product’s prescribing information includes a specific “Interchangeability Statement” describing its relationship to the reference product. This is listed in the FDA’s Purple Book, the official database of licensed biological products. That designation gives pharmacists the legal authority to make the substitution at the point of dispensing.
State laws add a layer of complexity. Each state sets its own rules about how pharmacists can substitute interchangeable biosimilars. Some states require the pharmacist to notify the prescriber after making the switch, while others impose fewer administrative requirements. These regulatory differences have a measurable effect on adoption. A study published in JAMA Health Forum found that insulin users in states with less restrictive substitution laws were significantly more likely to fill a biosimilar alternative, highlighting how state-level policy directly shapes whether patients actually benefit from interchangeability designations.
Why Interchangeability Matters for Drug Costs
Biologic medications occupy a unique and expensive corner of the drug market. They account for only about 5% of prescriptions in the United States but represent 51% of total drug spending as of 2024. Even with insurance, high deductibles and coverage gaps leave many patients paying substantial out-of-pocket costs for these treatments.
Biosimilars, including interchangeable ones, offer a meaningful price break. On average, biosimilars are priced 50% lower than the reference biologic was at the time of launch. Collectively, biosimilars have generated $56 billion in healthcare savings since 2015, with $20 billion saved in 2024 alone. Yet their market share remains below 20%, and only 10% of branded biologics currently have biosimilars in development. Making the interchangeability pathway easier to navigate could help close that gap by enabling automatic pharmacy substitution, which removes a significant barrier to patients actually receiving the lower-cost option.
The Growing List of Interchangeable Products
The FDA has steadily expanded the number of approved interchangeable biosimilars. As of early 2026, the list spans treatments for conditions ranging from cancer to bone loss to eye disease. Recent approvals include interchangeable versions of denosumab (used for osteoporosis and bone complications from cancer), pertuzumab (a breast cancer treatment), ranibizumab (for certain eye conditions), and pegfilgrastim (which helps prevent infections during chemotherapy). Multiple manufacturers have received approval for some of these reference products, meaning patients and pharmacists may soon have several interchangeable options to choose from for the same condition.
Despite this growth, the pipeline remains narrow relative to the opportunity. About 27% of high-value biologics with more than $500 million in annual sales still have no biosimilar in development. Expanding the interchangeability pathway, particularly by reducing the burden of switching studies, is one of the regulatory levers that could encourage more manufacturers to enter the market and bring additional competition to some of the most expensive drugs patients rely on.